The drugmaker behind Ozempic and Wegovy has cut its sales and profit targets in the face of intense competition from other weight-loss and diabetes treatments.<\/p>\n
Novo Nordisk warned over weaker-than-expected profits amid the recent growth of US rival Eli Lilly\u2019s Mounjaro and Zepbound injection treatments.<\/p>\n
The boss of the Danish pharmaceutical firm linked its reduced guidance to the market for weight-loss treatments being \u201cmore competitive than ever\u201d.<\/p>\n
Mike Doustdar, chief executive of Novo Nordisk, said: \u201cWhile we delivered robust sales growth in the first nine months of 2025, the lower growth expectations for our GLP-1 treatments, for diabetes and obesity, have led to a narrowing of our guidance.\u201d<\/p>\n
The firm said sales are set to rise by up to 11% this year. It had previously guided towards growth of up to 14%.<\/p>\n
It also reported that operating profits will rise by up to 7% this year, pulling down its previous guidance of up to 10%.<\/p>\n
It came as the business reported that sales in its diabetes and obesity care division grew by 12% in Danish kroner, or 15% at constant currency rates, over the first nine months of 2025.<\/p>\n
This included a stronger performance across obesity, with 7% growth in the diabetes-focused part of the division, which includes Ozempic.<\/p>\n
Meanwhile, operating profits grew by 5%, or 10% at constant currency rates, for the year so far.<\/p>\n
It said this included a nine billion kroner (\u00a36.7 billion) impact from one of restructuring costs.<\/p>\n
This came after the company launched a major overhaul in September, which included plans to cut around 9,000 jobs globally.<\/p>\n
Mr Doustdar added: \u201cOur company-wide transformation has already driven operational efficiencies, and we have a renewed focus that can deliver a range of potential treatment options that will serve millions more patients, mainly in obesity.<\/p>\n
\u201cWe aim to accelerate on all fronts to be able to compete better in dynamic and increasingly competitive markets.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"The drugmaker behind Ozempic and Wegovy has cut its sales and profit targets in the face of intense…\n","protected":false},"author":2,"featured_media":41514,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[5216,23467,2832,272,357,23466,280],"class_list":{"0":"post-41513","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-danish-kroner","9":"tag-growth-expectations","10":"tag-mike-doustdar","11":"tag-novo-nordisk","12":"tag-obesity","13":"tag-robust-sales-growth","14":"tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116241287488567380","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/41513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=41513"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/41513\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/41514"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=41513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=41513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=41513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}